New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
05:55 EDTABMD, ABMD, ABMD, ANGO, ANGO, ANGO, BAX, BAX, BAX, BDX, BDX, BDX, CAH, CAH, CAH, COV, COV, COV, EW, EW, EW, NVO, NVO, NVO, SYK, SYK, SYKSociety of Thoracic Surgeons to hold annual meeting
49th Annual Meeting of the STS is being held in Los Angeles on January 26-30.
Check below for free stories on ABMD;ANGO;BAX;BDX;CAH;COV;EW;NVO;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 14, 2014
06:22 EDTEWMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTEWEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
April 13, 2014
15:10 EDTEWMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTEWEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 11, 2014
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Subscribe for More Information
08:10 EDTCOVCovidien implements voluntary recall of devices
Subscribe for More Information
April 10, 2014
07:34 EDTABMDAbiomed shares attractive following recent weakness, says Stephens
Stephens believes Abiomed shares are attractively valued following their recent weakness given the stock's valuation relative to peers. The firm says Abiomed remains one of its top ideas and reiterates its Overweight rating and $34 price target on the stock.
April 9, 2014
19:01 EDTANGOOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTANGOAngioDynamics sees Q4 adjusted EPS 18c-21c, consensus 14c
Sees Q4 revenue $91M-$95M, consensus $93.17M.
16:09 EDTANGOAngioDynamics trades up after results, first look
Subscribe for More Information
16:08 EDTANGOAngioDynamics sees FY14 adjusted EPS 60c-63c had seen 63c-67c
Subscribe for More Information
16:06 EDTANGOAngioDynamics reports Q3 adjusted EPS 16c, consensus 9c
Reports Q3 revenue $88.2M, consensus $88.85M.
15:19 EDTANGONotable companies reporting after market close
Subscribe for More Information
April 8, 2014
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.
07:26 EDTEW, COVElsevier Business Intelligence to hold a conference
Subscribe for More Information
07:22 EDTBAX, NVOCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
April 4, 2014
05:14 EDTEWEdwards Lifesciences INTUITY Elite valve system receives CE Mark
Edwards Lifesciences announced it has received CE Mark for the advanced EDWARDS INTUITY Elite valve system. This next-generation, rapid deployment system facilitates smaller incisions in surgical aortic valve replacement, or AVR, procedures, and is built upon extensive evidence supporting the durability of the Carpentier-Edwards PERIMOUNT heart valve design.
April 3, 2014
07:04 EDTCAHCardinal Health acquisition an incremental positive, says Leerink
Subscribe for More Information
07:01 EDTBAXKamada announces U.S. proof-of-concept study with Glassia
Subscribe for More Information
05:29 EDTSYKBiomet reports Q3 adjusted net income $107.3M vs. $94.9M last year
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use